CRISPR One-Time Treatment Cuts Cholesterol for a Year
A single infusion of an experimental CRISPR gene-editing therapy has produced durable reductions in LDL cholesterol and triglycerides lasting at least one year, according to results from a Cleveland Clinic-led Phase 1 clinical trial presented at the 2026 European Society of Cardiology Congress and published simultaneously in the New England Journal of Medicine.
The findings represent a significant milestone in the quest to develop one-time treatments for cardiovascular disease, which remains the leading killer of Americans and people worldwide.
The Trial
The Phase 1a, first-in-human, open-label, dose-escalation study enrolled 15 adults ages 31 to 68 with uncontrolled high triglycerides and high LDL cholesterol, including patients with familial hypercholesterolemia, severe hypertriglyceridemia, and mixed dyslipidemias. The trial was conducted at six sites in Australia, New Zealand, and the United Kingdom between June 2024 and August 2025.
Participants received a single intravenous infusion of CTX310, an investigational CRISPR-Cas9 gene-editing therapy, at doses ranging from 0.1 to 0.8 mg/kg. The therapy targets the ANGPTL3 gene in the liver, switching it off. This gene produces a protein that blocks the breakdown of LDL cholesterol and triglycerides.
At the highest dose (0.8 mg/kg), the results were striking: ANGPTL3 levels dropped by a mean of 79% (maximum 89%) from baseline, triglycerides fell by a mean of 48% (maximum 78%), and LDL cholesterol decreased by a mean of 53% (maximum 84%). The Cleveland Clinic reported a 52.5% LDL reduction and 47.8% triglyceride reduction at 12 months.
“Building upon the initial data presented in November 2025, the durability of the lipid-lowering effect was impressive,” said Dr. Luke Laffin, Cleveland Clinic cardiologist and first author of the study. “It is encouraging that there were no serious safety events related to CTX310 in the trial and in the year following treatment.”
Safety Profile
The therapy was generally well tolerated, with no treatment-related serious adverse events, no dose-limiting toxicities, and no Grade 3 or higher liver transaminase changes. Minor reactions such as back pain and nausea resolved with medication. One participant experienced a temporary rise in liver enzymes that returned to normal.
CRISPR Therapeutics, the biotech company developing CTX310, noted that no new treatment-related safety events were observed during the extended follow-up period.
The favorable safety profile is partly explained by the therapy’s design: it replicates a naturally occurring genetic variant found in a population in Limone sul Garda, Italy, where people born with a loss-of-function mutation in the ANGPTL3 gene have naturally low cholesterol, lower heart disease risk, and no apparent adverse health consequences.
Addressing the Adherence Gap
The one-time treatment approach addresses a fundamental challenge in cardiovascular medicine: medication adherence. Approximately half of patients who start taking a daily statin stop within a year, according to TIME.
“As a preventive cardiologist, you’re really thinking, I’ll treat people chronically for many, many years,” Laffin said. “To have the possibility of giving a one-time cure is much more akin to other specialties, like a surgeon.”
Dr. Steven E. Nissen, senior author and Chief Academic Officer of the Cleveland Clinic Heart, Vascular and Thoracic Institute, emphasized the significance of the durability data: “What is compelling about this update is that the reductions in ANGPTL3, triglycerides, and LDL from a single infusion have persisted out to one-year, suggesting a sustained biological effect. A one-time treatment with this degree of durability could represent a meaningful advance in how we manage lifelong lipid disorders.”
A Growing Field
CTX310 is part of a broader wave of gene-editing approaches targeting cardiovascular disease. Earlier this year, Eli Lilly reported Phase 1b results for VERVE-102, a competing therapy targeting the PCSK9 gene using base editing technology, showing up to 62% LDL reduction in 35 patients.
Samarth Kulkarni, CEO of CRISPR Therapeutics, called the results “a pretty big win” from an efficacy standpoint. “The biggest promise of gene-editing in cardiovascular medicine is the notion of a one-time treatment that would be all you need,” he said. “Once you reduce levels of ANGPTL3, it remains durably reduced—presumably for life, but at least for one year. It’s very exciting.”
Independent experts expressed cautious optimism. Dr. Amrut Ambardekar, a cardiologist at the University of Colorado who was not involved in the study, noted: “You do a one-time treatment; you’re done. You don’t have to worry about it. I think that’s what’s exciting. I think the thing that we still are trying to figure out is safety, and so far the studies have been very small.”
Dr. Kiran Musunuru, a cardiologist at the University of Pennsylvania who was not involved, said, “The data look good in terms of stability.” He predicted the therapy might become an option for patients in the early 2030s.
Market Reaction and Next Steps
Despite the positive clinical data, CRISPR Therapeutics’ stock (CRSP) dipped approximately 3%, with Morgan Stanley noting that investor focus is on future trial readouts rather than the current results, according to Profit Confidential.
The company has advanced CTX310 into a Phase 1b clinical trial with U.S. and ex-U.S. sites, using a fixed flat dose equivalent to the most efficacious Phase 1a dose. Results from the severe hypertriglyceridemia cohort are expected in the second half of 2026.
Patients in the trial are required by the FDA to be followed for 15 years post-treatment, reflecting the long-term safety monitoring mandated for all gene-editing therapies.
What to Watch
Several critical questions remain: Will the cholesterol-lowering effect persist beyond one year? Will results hold in larger Phase 1b and Phase 3 trials? How will CTX310 compare to Eli Lilly’s VERVE-102 approach? And will the therapy prove cost-effective compared to daily statin therapy?
As The Insight Post reported, the approach that once seemed “almost outlandishly far out” has inched closer to reality as evidence accrues that it works—and that the results stick.
For the hundreds of millions of people worldwide living with high cholesterol, the prospect of a one-time treatment that could replace decades of daily medication represents a potentially transformative shift in how cardiovascular disease is managed. The next phases of clinical testing will determine whether that promise becomes reality.